Waning immunity puts preteens/teens at risk! Immunity wanes 5-10 years following last pertussis vaccination [1] Pertussis is highly contagious — up to 90% [2] ACIP recommends all adolescents 11 to 18 years receive a Tdap booster shot [3] Preferred age for vaccination is 11 to 12 years Adolescents who have already received a booster dose of Td are encouraged to get a dose of Tdap Tdap can be given at the same time, at separate sites, with other vaccines Pertussis: A vaccine-preventable disease on the rise. Tenfold increase in reported adolescent cases in the last decade [4,5] 38% of reported cases were in adolescents in 2004 [4] Underreported — actual cases may exceed 1 million per year [6,7] A BOOST of confidence with worldwide experience[8] The antigens contained in BOOSTRIX have been distributed in: – a non-US formulation of BOOSTRIX since 1999 [8]        The US formulation of BOOSTRIX contains 0.3 mg of        aluminum per dose, is indicated for ages 10-18, and is        preservative free. The non-US formulation of BOOSTRIX        contains 0.5 mg of aluminum per dose, has a        preservative, and is indicated for ages 4 and older. [9] – over 100 million doses of INFANRIX and PEDIARIX in the US [10] – BOOSTRIX contains reduced levels of antigens appropriate for adolescents Safety profile comparable to Td alone [11] Click Here for Frequently Asked Questions Important Safety Information In clinical studies, adverse events in adolescents receiving BOOSTRIX included pain, redness, and swelling at the injection site, headache, fatigue and gastrointestinal symptoms. As with other vaccines, rare adverse events may occur. Adverse events in children receiving INFANRIX included injection-site reactions (erythema, swelling, and tenderness), fever, irritability, and drowsiness. As with any vaccine, vaccination with BOOSTRIX or INFANRIX may not protect 100% of susceptible individuals. Hypersensitivity to any component of BOOSTRIX or INFANRIX is a contraindication. *CPT is a registered trademark of the American Medical Association. BOOSTRIX, INFANRIX, PEDIARIX and Tip-Lok are registered trademarks of GlaxoSmithKline. INFANRIX Prescribing Information Home   FAQs   Pertussis Information   BOOSTRIX Prescribing Information   Important Safety Information   Material Safety Data Sheet   STEPP Compliance Program This site is intended for US healthcare professionals only. © 1997-2008 GlaxoSmithKline. All Rights Reserved. Legal Notices | Privacy Statement | Medicine Savings | Contact Us Manufactured by GlaxoSmithKline Biologicals, Rixensart, Belgium Distributed by GlaxoSmithKline, Research Triangle Park, NC 27709 Complete Prescribing Information is provided in Adobe's Portable Document Format (PDF). To view this file, you will need to have the Adobe® Acrobat® Reader™ plug-in installed in your browser. If you do not have the Acrobat Reader, follow the link to download a copy.